HomeSGX-LISTED COMPANIESV2Y Corporation Interim Financial Statements 1H 2025

V2Y Corporation Interim Financial Statements 1H 2025

Published on

spot_img

This financial period marks a significant shift for V2Y Corporation Ltd. The company has refocused its strategy by divesting from underperforming sectors to concentrate on its core, revenue-generating Insurtech business. This strategic realignment, coupled with new funding, aims to strengthen the company’s financial footing for future growth.

• The Group’s revenue saw a substantial increase, driven by first-quarter sales from now-divested businesses

• Losses narrowed, influenced by the proceeds from selling off its food, beverage, and distribution segments

• A strategic pivot now sees the company focusing its resources on the promising Insurtech division

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...